Risk Reassessment of Differentiated Thyroid Cancer in Ahvaz, Iran: A Cross-sectional Retrospective Study

Jahanshahi, Alireza; Sarshoori, Atefeh Asoodeh; Rashidi, Homeira; Zaman, Ferdos

doi:10.5812/ijem-130434

Cited by 1 publication

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most DTCs were of papillary type and predominantly affected female patients; the majority were at stage I. These results are similar to the Jahanshahi et al's study conducted in Ahvaz, Iran [ 17 ]. The ATA recurrence risk is a validated tool to assess the risk of recurrence of DTC.…”

Section: Discussionsupporting

confidence: 88%

“…Jahanshahi et al conducted a cross-sectional study to describe the risk stratification of DTC in Ahvaz, Iran [ 17 ]. Their study found that risk stratification varied significantly based on dynamic risk, and when comparing with their results, they found none of the patients with high ATA risk achieved ER, whereas in our study, 3/6 patients achieved this result.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah

Jasim,

Hussein,

Alidrisi

et al. 2023

Cureus

View full text Add to dashboard Cite

Background Differentiated thyroid cancer is a common endocrine cancer; most of it has an indolent course and favorable outcomes, with a subset of patients having the risk of disease recurrence, which can be assessed using the fixed American Thyroid Association (ATA) risk stratification system or the dynamic response to therapy risk stratification that can be modified during patients follow-up. Aim The aim of this article is to assess the risk stratification of patients having differentiated thyroid cancer. Methods This is a retrospective cross-sectional study in which we evaluated medical records of 75 patients having differentiated thyroid cancer to assess the baseline ATA risk of recurrence and compared it to the results of dynamic risk stratification in response to therapy at 6-12 months post-surgery and at the last visit. Thyroglobulin level, anti-thyroglobulin antibody, thyroid ultrasound, and cytopathological examination were used to determine dynamic response to therapy and divided subjects into four groups: excellent response (ER), biochemical incomplete response (BIR), structural incomplete response (SIR), and indeterminate response (IR). Results At baseline, 55 patients had low risk, 14 patients had intermediate risk, and six patients had high risk. At 6-12 months post-surgery, in the low-risk group, ER, BIR, and IR responses were observed in 56.4%, 5.5%, and 38.2% of patients, respectively, and none of them exhibited SIR. In the intermediate-risk group, ER, BIR, and IR responses were observed in 57.1%, 21.4%, and 21.4% of patients, respectively, and none exhibited SIR. Among the high-risk group, two patients had ER, two patients had BIR, one patient had IR, and one patient had SIR. At the last visit, ER, BIR, and IR were observed in 65.5%, 9.1%, and 25.5% of low-risk patients, respectively, and no patient developed SIR. In the intermediate-risk group, ER, BIR, and IR were observed in 50%, 21.4%, and 28.6% of patients, respectively, and no patients developed SIR. Among the high-risk group, three patients achieved ER, one had BIR, one had IR, and one had SIR. Conclusion Most of the differentiated thyroid cancers in this study are low-risk. Dynamic risk stratification appears to be an effective tool in the follow-up of this population of patients having differentiated thyroid cancer.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%